Tagged with oncology,

Taiwan Ten years after its creation in 2005, InnoPharmax was ranked seventh fastest growing technology company in Taiwan in Deloitte’s “Technology Fast 500 Asia Pacific” annual ranking. CS Hsu, founder and president of InnoPharmax, introduces the company’s most fundamental asset – OralPAS®, its unique technology platform, and documents the promising development…

Greece Appointed in the midst of the Greek economic crisis, compounded by significant changes at the corporate Merck brand, Merck Greece’s MD, Konstantinos Kofinas, did not shy away from challenges. He speaks about his leadership approach, Merck’s key therapeutic areas in Greece, as well as industry collaboration in creating a sustainable…

Mexico Abelardo Meneses García, General Director at the National Cancer Institute of Mexico (INCan), explains the evolution of cancer’s footprint in Mexico and showcases how the institute has been investing in enlarging its capabilities to become the national and regional reference for cancer treatment. Could you please introduce to our international…

Taiwan Terry Lin, general manager, and Freia Wei, director for international business at UniPharma, on the company’s move from specialty distribution to drug development and diagnostic products. With an upcoming IPO, UniPharma is considering both organic and inorganic development opportunities to further nurture its geographical expansion. Being one of the best-established…

Mexico Dr. Marco A. Martinez Rios, General Director of the National Institute of Cardiology in Mexico elaborates on the institution’s rich history in Mexico and its contributions to cardiology through research, teaching and treatment. As the general director of the National Institute of Cardiology, could you introduce yourself to our international…

Mexico Andrés Matesanz, general manager at DCS Pharma Mexico, explains how the merger between Dolder and Chemswiss has enlarged the capabilities and the offering of the company in Mexico and showcases the added value of DCS Pharma being considered the fastest option within the industry. ChemSwiss has recently merged with Dolder.…

Philippines Bert van Dierendonck and Alec van Dierendonck, Founder and Country Manager, as well as father and son, discuss Euro Generics’ unique history in the country and their road to becoming one of the fastest growing pharmaceutical companies in the Philippines. They also discuss their strategies for staying ahead of market…

Taiwan Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have allowed PharmaEngine to become the first Taiwan-based company to receive FDA approval for a locally-developed oncology treatment, as well as…

Ireland Shane Ryan, in his first month as Country Lead for Takeda Products Ireland, speaks about his mandate to position Takeda as the leader in IBD and oncology with exciting new product launches, the evolving pharmaceutical and healthcare landscape in Ireland, and the drive to help patients that motivates him every…

Ireland Deirdre Bourke, Country Lead at Eli Lilly’s Irish affiliate, highlights the strategic importance of Ireland to Lilly’s global operations, their exciting upcoming pipeline, the challenges and opportunities she foresees for Lilly in Ireland, and her own professional transition from managing Lilly’s diabetes portfolio to Lilly’s overall commercial activities in Ireland.…

Philippines Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped to expand access to affordable medications to the Filipinos, still pointing out that there is much room for expansion in…

Mexico Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has been critical to Janssen’s success in a country noteworthy for the complexity of its public health system. You took over…